Looking for Tocilizumab found 21 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Tocilizumab
(Biosimilars avaliable)
|
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation (10.01.03)
|
|
MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation (05.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA518: Tocilizumab for treating giant cell arteritis (10.01.03)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
|
